NCT02400385View on ClinicalTrials.gov

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Melanoma
Interventions
DRUG

sunitinib

sunitinib 50mg/day po, 4 weeks on 2 weeks off

DRUG

nivolumab

nivolumab 3mg/kg IV ever 2 weeks

Trial Locations (1)

94115

California Pacific Medical Center Research Institute, San Francisco

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

California Pacific Medical Center Research Institute

OTHER